News

Following extensive research, Crown has claimed to have developed a supplement with superior benefits and efficacy compared to existing supplements. The company believes that the incorporation of new

Indicated for patients with exocrine pancreatic insufficiency (EPI), 36,000 lipase-unit dose of the pancreatic enzyme replacement therapy was approved by the FDA. University of Pittsburgh gastroenterology, hepatology and

According to the strategic alliance, both the organizations will jointly advance the ongoing development of AB-16B5 and distribute the downstream economics on an equal basis in territories outside

Oramed Pharmaceuticals CEO Nadav Kidron said, "This grant will assist Oramed as we initiate Phase 2 clinical trials in the US on our oral insulin candidate." The funds

With the possibility for extension, the patent entitled ‘Fusidic Acid Dosing Regimens for Treatment of Bacterial Infections’ protects US market exclusivity to 2029. Cempra chief executive officer Prabhavathi

The company purchased intellectual property of the decontamination and infectious disease control system from L-3 Communications. Expected to boost the functionality of the company’s product line, the new

The patent includes the use of monoclonal antibodies, including the company’s therapeutic antibody iSONEP that binds sphingosine-1-phosphate (S1P). Lpath vice president, founder, and an inventor of the granted

Indicated for patients with relapsing-remitting multiple sclerosis (RRMS), the higher dose offers subcutaneous administration of thrice a week dosing regimen. Copaxone 20mg/1mL dose is currently approved for subcutaneous

The deal will assess the Durasert technology, pSivida’s core technology system, for certain ophthalmology products of the undisclosed pharmaceutical company. The Durasert technology system is designed to deliver